Recombinant Human Steroid Hormone Receptor Err1 (ESRRA) Protein (GST)

Beta LifeScience SKU/CAT #: BLC-04033P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Steroid Hormone Receptor Err1 (ESRRA) Protein (GST)

Beta LifeScience SKU/CAT #: BLC-04033P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Steroid Hormone Receptor Err1 (ESRRA) Protein (GST) is produced by our E.coli expression system. This is a full length protein.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb P11474
Target Symbol ESRRA
Synonyms Err 1; ERR a; ERR alpha; ERR-alpha; Err1; ERR1 protein; ERR1_HUMAN; ERRa; ERRalpha; ESRL 1; ESRL1; ESRR A; Esrra; Estrogen receptor like 1; Estrogen receptor related 1; estrogen receptor related receptor alpha; Estrogen receptor-like 1; Estrogen related receptor alpha; Estrogen-related receptor alpha; Estrra; hERR1; NR3B1; Nuclear receptor subfamily 3 group B member 1; Steroid hormone receptor ERR1
Species Homo sapiens (Human)
Expression System E.coli
Tag N-GST
Target Protein Sequence MSSQVVGIEPLYIKAEPASPDSPKGSSETETEPPVALAPGPAPTRCLPGHKEEEDGEGAGPGEQGGGKLVLSSLPKRLCLVCGDVASGYHYGVASCEACKAFFKRTIQGSIEYSCPASNECEITKRRRKACQACRFTKCLRVGMLKEGVRLDRVRGGRQKYKRRPEVDPLPFPGPFPAGPLAVAGGPRKTAAPVNALVSHLLVVEPEKLYAMPDPAGPDGHLPAVATLCDLFDREIVVTISWAKSIPGFSSLSLSDQMSVLQSVWMEVLVLGVAQRSLPLQDELAFAEDLVLDEEGARAAGLGELGAALLQLVRRLQALRLEREEYVLLKALALANSDSVHIEDAEAVEQLREALHEALLEYEAGRAGPGGGAERRRAGRLLLTLPLLRQTAGKVLAHFYGVKLEGKVPMHKLFLEMLEAMMD
Expression Range 1-423aa
Protein Length Full Length
Mol. Weight 72.5kDa
Research Area Epigenetics And Nuclear Signaling
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces the expression of PERM1 in the skeletal muscle.
Subcellular Location Nucleus. Cytoplasm.
Protein Families Nuclear hormone receptor family, NR3 subfamily
Database References

HGNC: 3471

OMIM: 601998

KEGG: hsa:2101

STRING: 9606.ENSP00000000442

UniGene: PMID: 30185207

  • This work reveals a molecular mechanism by which ERRalpha-induced metabolic reprogramming promotes survival of lapatinib-resistant cancer cells. PMID: 27402251
  • data showed that activation of NF-kappaB/IL-6 is involved in ERRalpha induced migration and invasion of non-small cell lung cancer cells; it suggested that ERRalpha might be a potential target for non-small cell lung cancer treatment PMID: 29862528
  • Results show that ERRA is an interacting partner of PGC1a in a subset of human melanoma cells. Also, ERRA promotes mitochondrial oxidative metabolism in melanoma cells. PMID: 28596418
  • LSD1 and ERRalpha coregulate several target genes involved in cell migration, including the MMP1 matrix metallo-protease, also activated through H3K9 demethylation at the transcriptional start site. PMID: 28348226
  • TGF-beta treatment can trigger the epithelial-mesenchymal transition of osteosarcoma cells via ERRalpha/Snail pathways. PMID: 27532429
  • LC3B and ESRRA might be a useful prognostic factor in patients with muscle-invasive bladder cancer. The co-expression of LC3B and ESRRA might be a prognostic and therapeutic target for patients with bladder cancer. PMID: 29599373
  • These findings indicate that ERRalpha may serve as a novel molecular target for the treatment of endometrial cancer PMID: 27153547
  • Gls is a novel ERRalpha target gene. PMID: 27501743
  • can trigger the proliferation and migration of colorectal cancer cells via up regulation of IL-8 PMID: 28993941
  • curcumin suppressed the ERRalpha gene expression through upregulation of miR-125a. Data from this study revealed a novel mechanism for curcumin-mediated apoptotic cell death, which involves tumor cell killing via activating miR-125a/ERRalpha pathway. PMID: 27231954
  • blocking the ERRalpha-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERRalpha and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression. PMID: 27041564
  • results suggest that the decreased expression of miR-135a in metastatic tumors leads to elevated ERRalpha expression, resulting in increased cell invasion capacities. PMID: 27227989
  • HO-1-derived CO enhances mitochondrial biogenesis in astrocytes by activating L-type Ca(2+) channel-mediated PGC-1alpha/ERRalpha axis, leading to maintenance of astrocyte function and neuroprotection/recovery against damage of brain function PMID: 27639646
  • in ERalpha negative breast cancer, the low level of ERalpha reduced miR-497 expression, which promoted ERRalpha expression that enhanced cell proliferation, migration, and invasion by increasing MIF expression and MMP9 activity. PMID: 27456360
  • these data show that ERRalpha expression predicts response to tamoxifen treatment, and ERRalpha could be a biomarker of tamoxifen sensitivity and a prognostic factor in TNBC. PMID: 26542058
  • ERRalpha suppression inhibits angiogenesis in HUVECs PMID: 26586335
  • Incomplete autophagy and cell death by a necrotic processes, as a consequence of the cell energy failure, induced by pharmacological reduction of ERRalpha in adrenocortical carcinoma cells. PMID: 26312764
  • CD68(+)CD163(+) macrophages secreted cytokines, such as IL17A, that upregulated ERalpha expression. PMID: 26744532
  • Inhibition of ERRalpha suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin. PMID: 26160845
  • mediates metabolic transition, which is required for induced pluripotency PMID: 25865501
  • An ERRalpha 23-repeats polymorphisms with BMD in postmenopausal Egyptian women. PMID: 25903400
  • Over-expression of ESRRA due to its gene amplification in OSCC PMID: 26639757
  • targeting of ERRalpha and pathways regulating transcriptional HIF-2alpha are promising therapeutic avenues in neuroblastoma PMID: 25912138
  • ERRalpha promoted the migration and invasion of A549 cells by inducing EMT, and Slug was involved in the process. Targeting ERRalpha might be an efficient approach for lung cancer treatment. PMID: 25480584
  • control exerted by ERRalpha on RHOA stability is required for directional migration PMID: 25288732
  • These results suggest ERRalpha activation as a mechanism of tumor aggressiveness and imply that targeting ERRa may be a promising approach in ovarian cancer treatment. PMID: 24419103
  • this study demonstrated that ERR alpha plays an important role in the development of MTX resistance through blocking MTX-induced ROS production and attenuating the activation of p53 mediated apoptosis signaling pathway PMID: 24967384
  • Estrogen receptor alpha coupled to the Bmi1 regulation pathway plays an important role in breast cancer progression. PMID: 24559156
  • miR-125a post-transcriptionally regulates ESRRA in oral squamous cell carcinoma PMID: 25266720
  • The frequency of the ESRRA/C11orf20 gene fusion in serous ovarian carcinomas of stages III and IV must be very low. PMID: 24504521
  • Cell cycle dependent oscillatory expression of estrogen receptor-alpha links Pol II elongation to neoplastic transformation. PMID: 24979764
  • ERRalpha is downregulated in uterosacral ligaments in pelvic organ prolapse PMID: 23700042
  • ERRalpha can promote the hypoxic growth adaptation of prostate cancer cells via a protective interaction with HIF-1alpha, suggesting ERRalpha as a potential therapeutic target for cancer treatment. PMID: 24425001
  • Data indicate that a stable cell clones have an intact peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha)/estrogen-related receptor alpha (ERRalpha) axis can be used to detect environmental chemicals that act on the signaling pathway. PMID: 24457025
  • There are 3 ERRalpha response elements (ERR response element, ERRE) in the osteocalcin promoter, and ERRalpha interacted cooperatively with PGC-1alpha could improve the osteocalcin promoter activity. PMID: 23788330
  • analysis of twenty members across three generations identified a rare missense mutation in the estrogen-related receptor alpha (ESRRA) gene that segregated with eating disorders PMID: 24216484
  • ERRalpha coordinates colon cancer cell proliferation and tumorigenic capacity with energy metabolism. PMID: 23720198
  • analysis of clinical datasets from liver tissues showed a negative correlation between expressions of ERRalpha and PTEN in patients with liver cancer. PMID: 23836899
  • the expression of ERRalpha mRNA was significantly increased during the late stage of osteogenic differentiation of human periodontal ligament tissue-derived mesenchymal stem cells. PMID: 23525223
  • ERRa and OPN are co-expressed and higher in colorectal cancer cells as opposed to normal mucosa. Data provide compelling evidence that OPN is a direct target of ERRa, the induction of which could clearly contribute to colorectal cancer pathogenesis. PMID: 23680656
  • ERRalpha can act as a transcriptional activator of Runx2-I in presence of peroxisome proliferator activated receptor gamma coactivator-1 alpha (PGC-1alpha). PMID: 23403054
  • the role played by ERRalpha in the regulation of lactate dehydrogenases A and B PMID: 23516535
  • A possible role of ERRalpha in adrenal development and adrenocortical carcinoma. PMID: 23123734
  • ERRalpha and PGC-1beta are key players in the etiology of breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERalpha on ERBB2 expression. PMID: 20961995
  • Data identify ERRalpha as a new regulator of the Wnt-signaling pathway during osteoblast differentiation, through a cell-intrinsic mechanism not affecting beta-catenin nuclear translocation. PMID: 22333182
  • ERRalpha-induced adipogenesis is triggered by modulating the expression of PGC-1beta. PMID: 21732060
  • Data observed in DMD and aging skeletal muscle enrichment in motifs for candidate transcription factors that may coordinate either the immune/fibrosis responses (ETS1, IRF1, NF1) or the mitochondrial metabolism (ESRRA). PMID: 22096509
  • these data suggest that RaRF sequesters ERRalpha in the nucleolus through a specific interaction, thereby inhibiting its transcriptional activity. PMID: 22266318
  • Exposure to XCT790, a synthetic inverse agonist of the orphan nuclear oestrogen-related receptor alpha (ERRalpha), also induced EGFR and HB-EGF expression to the same extent as AM251. PMID: 21449913
  • FAQs

    Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

    Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

    Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

    Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

    Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

    Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

    To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

    Recently viewed